Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM
Because of these limitations, the findings should be interpreted as real-world associations rather than definitive causal evidence
Electrolyte and acid-base disorders in inflammatory bowel disease
US Address Perfect 1 Palmer Square, Suite 441, Princeton, NJ 08542
10.1016/j.apsb.2021.02.001 179 YuanK.LiX.LuQ.ZhuQ.JiangH.WangT.et al (2019)
However, one large multicenter, double-blinded, randomized clinical trial of sivelestat was stopped due to the negative trend in long-term mortality rate, in which follow-up data showed neither effects on primary endpoints of ventilator-free days and 28-day all-cause mortality nor physiology and clinical outcomes (Zeiher et al., 2004)